Proteomics Facility Director
Ph.D. 2000, University of Geneva, Switzerland
Post-Doc. 2003, University of Missouri, Columbia, MO , USA
Microbiology and Immunology
Biomarkers Discovery Studies of HIV, Cancer, Substance of abuse and Multiple Sclerosis.
HIV-1 Gp120 Effect on Glioma Tumor Growth and Chemotherapy Resistance via UPR ER Stress Mechanisms.
Anti-cancer and anti-HIV mechanistic effects of natural compounds for cancer and HIV treatment.
Dr. Boukli’s research uses state-of-the-art screening platform technologies, including target quantitative proteomics multiplexing with isobaric tags approaches, molecular and flow cytometric analysis in studies of cell cycle, cell proliferation and cell death for the detection of biomarkers and molecular signatures in HIV, substance of abuse, cancer and multiple sclerosis. Dr. Boukli is also interested in how Endoplasmic Reticulum (ER) stress responses and cell fate decision can regulate the network of apoptotic and survival signal events in different cells and systems and the anti-cancer and anti-HIV mechanistic effects of natural compounds for cancer and HIV treatment as some of her publications demonstrate (Boukli et al, 2010, Boukli et al, 2011, Boukli et al, 2012, Rivera et al, and Boukli, 2016, Lopez et al, and Boukli, 2017, Rodriguez et al, and Boukli, 2018). Dr. Boukli has also been active in training young investigators, both individually (as a mentor and proteomics facility resource, post-doctoral fellows, medical students, Master and PhD trainees) and in the classroom (where she teaches molecular biology to medical and PhD students and has developed a proteomics graduate-level course and several workshops on proteomics in clinical research).
Universidad Central del Caribe
P.O. Box 60327
Bayamón, PR 00960-6032
Tel (787) 798-3001 ext. 2080
Tel Labs (787) 798-3001 Ext. 2090, 2162